

**Charles Joel Rosser, M.D., M.B.A., F.A.C.S.**

**CURRICULUM VITAE**

(March 19, 2019)

**Professional Contact Information**

Division of Urology  
Cedars-Sinai Medical Center  
8635 E 3<sup>rd</sup> St  
Los Angeles, CA 90048  
Tel: 310-423-5942  
Email: Charles.rosser@cshs.org

**EDUCATION:**

UNDERGRADUATE AND GRADUATE EDUCATION

1991 B.S. Fairleigh Dickinson University (Biology), Madison, NJ, Summa Cum Laude  
1994 M.D. UMDNJ - Robert Wood Johnson Medical School, Piscataway, NJ  
2008 M.B.A. University of Phoenix School of Business, Jacksonville, FL

POSTDOCTORAL TRAINING

Internship and Residency:

1994 Intern Physician, Wake Forest University School of Medicine, Winston-Salem, NC  
1995-1999 Urology Resident Physician, Wake Forest University School of Medicine, Winston-Salem, NC  
2000 Chief Resident of Urology, Wake Forest University School of Medicine, Winston-Salem, NC

Fellowship:

2003 Clinical Fellow in Urologic Oncology, UT MD Anderson Cancer Center  
2010 Robotic Assisted Laparoscopic Surgery Mini-Fellowship, UT MD Anderson Cancer Center

**LICENSURE:**

1994 – 2018 North Carolina License No. 9600268  
2000 – 2018 Texas License No. L 1189  
2003 – 2018 Florida License No. ME 88129  
2012 – Hawaii License No. MD16990  
2018 – California License No. 158684

## **BOARD CERTIFICATION:**

1995            Diplomate, National Boards parts 1, 2 & 3 (USMLE ID: 4-012-811-8)  
3/2005           Diplomate, American Board of Urology  
                    Recertification: 2013 (Maintenance of Certification status: active)

## **PROFESSIONAL EXPERIENCE:**

### **Present Position:**

1/2019 –            Staff physician/SOCCI Clinical Trial Office Medical Director  
                    Cedars-Sinai Medical Center, Los Angeles, CA

### **Previous Position:**

7/2003 – 9/2009    Associate Professor of Urology (Tenured)/Director of Urologic  
                            Oncology, University of Florida College of Medicine, Gainesville,  
                            FL  
10/2009 – 7/2013    Section Chief, Urologic Oncology, MD Anderson Cancer Center  
                            Orlando  
10/2009 – 12/2013    Professor of Surgery, University of Central Florida College of  
                            Medicine, Orlando, FL  
1/2014 – 12/2018    Professor (tenure)/Associate Center Director for Translational and  
                            Clinical Research, University of Hawaii Cancer Center, Honolulu, HI  
4/2014 – 1/2019      Staff physician Queen’s Medical Center, Honolulu, HI

## **PROFESSIONAL ACTIVITIES:**

### **Committee Services:**

#### **Other Committee Services:**

10/2003 – 10/2005	Protocol Review Committee	Uni. Of Florida
5/2005 – 7/2006	Tissue Review Committee	Uni. Of Florida
7/2006 – 9/2009	GU Tissue Bank Committee	Uni. Of Florida
1/2007 – 6/2014	AUA CME Conflict of Interest Panel	AUA
6/2008 –	AUA Office of Education - Content Reviewer	AUA
10/2008 – 6/2011	Congressionally Directed Medical Research Programs	DOD
6/2009 – 5/2010	Update Literature Review (ULR) for Cryosurgery for Clinically Localized Prostate Cancer	AUA
9/2010 – 3/2012	MD Anderson Cancer Physician Quality Assurance	MDACCO
6/2012 – 10/2015	Congressionally Directed Medical Research Programs	PCRP
4/2012 – 6/2018	SBUR Membership Committee	SBUR
7/2010 – 6/2013	Uni. of Central Florida College of Med Admissions	UCF
9/2012 – 1/2014	Florida Urological Society Bylaws Committee	FUS
6/2012 – 7/2015	Cryoablation On Line Database (COLD Registry)	Endocare
7/2013 –	AUA International Academic Fellowship Committee	AUA
3/2015 – 12/2018	Protocol Review and Monitoring Committee	Uni. of Hawaii

3/2015 – 12/2018	Space utilization committee	Uni. of Hawaii
2/2016 –	NCI (NIH) CSR/Cancer Biomarker Study Section	NIH
4/2016 – 12/2018	Pathology review committee	Uni. of Hawaii

**Professional Associations/Society Memberships:**

6/1995 –	American Urologic Association, Inc.
6/1995 –	Southeastern Section of the American Urologic Association, Inc.
3/1999 –	American Association of Clinical Urologists
6/1999 –	American Association for Cancer Research
1/2000 –	Society of Urologic Oncology
2/2004 – 2014	Florida Medical Association
3/2004 –	Society of Basic Urologic Research
6/2006 –	Fellow American College of Surgeons
3/2009 –	American Society of Clinical Oncologist
7/2012 –	American College of Healthcare Executives

**Editorial Services:**

8/2009 – 10/2014	BMC Urology, Section Editor
4/2011 – 6/2018	BMC Cancer, Section Editor
2/2015 –	BMC Pilot & Feasibility Studies, Associate Editor

**HONORS AND SPECIAL AWARDS:**

10/1989	Phi Zeta Kappa Honor Society
5/1994	Senate Commendation State of New Jersey
4/1999	First Prize for Resident/Fellow Poster Presentation: Resident's and Fellow's Research Day
7/2000 –	American Foundation of Urologic Disease Scholarship
6/2002	
3/2005	University of Florida Research Day Best Poster (1 <sup>st</sup> and 2 <sup>nd</sup> prize in basic science)
6/2006	Distinguished Physician Florida Medical Association
10/2006	American Cancer Society Research Scholar
10/2007	University of Florida Research Day Best Poster (1 <sup>st</sup> prize in basic science, 2 <sup>nd</sup> prize in clinical)
4/2008	Young Investigator Award Society for Basic Urologic Research
5/2009	Strathmore's Who's Who
1/2010	BMC Urology Spotlight Associate Editor
2/2010	America's Top Urologist
2/2011	AUA International Exchange Scholar
3/2012	America's Top Urologist
3/2011	America's Top Urologist
11/2014	Weimann Award Translational Research

**RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:**

**Active/Ongoing:**

5/1/2016-4/30/2021

NIH/NCI 1R01CA198887 Multiplexed protein biomarker-based assay

Annual funding cost \$623,456

Role: PI, 15% effort

**Inactive/Completed:**

1/1/2006-12/30/2008

NIH/NCI 5 R21 CA102386 Antioxidant interactions with prostate cancer treatments

Annual funding cost: \$125,000

Role: Co-Inv, 5% effort

6/1/2005-5/31/2008

FL DOH New Investigator Award Genomic analysis of voided urine to detect bladder cancer

Annual funding cost: \$125,000

Role: PI, 10% effort

7/1/2006-12/30/2010

ACS Research Scholar Award RSG-06-265-01-MBC The role of p37 in prostate cancer invasion

Annual funding cost: \$250,000

Role: PI, 15% effort

7/1/2008-6/30/2011

FAMRI New Investigator Award Genomic Analysis of Urine to Detect Bladder Cancer

Annual funding cost: \$125,000

Role: PI, 10% effort

7/1/2011-6/30/2012

FL DOH SBIR Diagnostic Assay for Bladder Cancer

Annual funding cost: \$100,000

Role: Co-Inv, 5% effort

9/1/2007-8/31/2011

NIH/NCI 5 RO1 CA116161-01 Toward a non-invasive molecular test for bladder cancer detection

Annual funding cost: \$250,000

Role: Co-Inv, 5% effort

7/1/2010-6/30/2013

FL DOC TSP A Multidisciplinary Approach to Improve Patient Outcome in Bladder Cancer - A tobacco-related disease

Annual funding cost: \$500,000

Role: PI, 25% effort

12/1/2011-11/30/2012

DOD Prostate award - Exploration/Hypothesis Development Role of Mycoplasma ABC Transporter (p37) in Metastatic Prostate Cancer in a Mouse Model

Annual funding cost: \$100,000  
Role: PI, 5% effort

2/1/2012-1/30/2013

FL DOH STTR Development of a panel of monoclonal antibodies to a validated bladder cancer diagnostic signature

Annual funding cost: \$100,000  
Role: PI, 5% effort

9/1/2013-3/30/2016

NIH/NCI 5 R44 CA173921 03 Development of molecular assays for non-invasive bladder cancer detection

Annual funding cost  
Role: Co-Inv, 5% effort

6/1/2014-5/30/2015

Weinman Innovator Award for Translational Research Development of multiplex assay to detection urine-based biomarkers

Annual funding cost: \$50,000  
Role: PI, 0% effort

6/1/2017-1/30/2019

NIH/NCI 3 P30 CA071789 Hawaii Cancer Center Support Grant - CPDM and PRMS

Annual funding cost  
Role: Co-Inv, 20% effort

5/1/2017-2/30/2019

NIH/NCI 1R01CA198887-S Multiplexed protein biomarker-based assay

Annual funding cost \$45,123  
Role: PI, 0% effort

**Pending Grants:**

5/1/2019-4/30/2021

NIH/NCI 1R01CA198887-S Multiplexed protein biomarker-based assay

Annual funding cost \$125,000  
Role: PI, 2% effort

**RESEARCH FOCUS AND INTERESTS:**

Basic & Translational Research.

We have developed and tested a multiplex ELISA assay that incorporates our 10 validated biomarkers in a non-invasive test to detect bladder cancer. The assay is currently in a phase 3 multicenter international study and is funded by my current NIH/NCI R01 grant.

We have identified CXCL1 as a druggable target within the tumor cells and tumor stroma. We have developed a humanized monoclonal antibody and will begin to test it in preclinical models.

We performed initial studies on IL-15 (ALT-803) in human bladder cancer. After the results of our phase Ib and phase II study, FDA gave ALT-803 fast track status and we stand poised to conduct a phase III trial once the phase II data is mature to report.

### **TEACHING ACTIVITIES:**

#### **Clinical Teaching**

- 7/2003 – 9/2009 University of Florida College of Medicine Faculty –  
Involved in resident education in the ward/consult, clinic and operating room.  
Lectured PA students on genitourinary anatomy and conditions.  
Clinical research mentor to 3 medical students and 2 undergraduate students.
- 10/2009 – 12/2013 University of Central Florida College of Medicine Faculty –  
Clinical research mentor to 5 medical students.
- 1/2012 – 12/2013 Florida State University College of Medicine Faculty –  
Involved in medical student education in ward/consult, clinic and operating.
- 4/2019 – CSMC Division of Urology Faculty –  
Involved in resident education in the ward/consult, clinic and operating room.

#### **Non-Clinical Teaching**

- 8/2004 – 9/2009 University of Florida College of Medicine Faculty –  
Hosted 7 PhD students and 2 MS students in the laboratory and one PhD committee
- 10/09 – 12/2013 University of Central Florida Faculty –  
Hosted 3 post-doctorate fellows in translational research laboratory
- 4/2014 – University of Hawaii Molecular Biology Bioengineering PhD Graduate Faculty – Hosted 3 PhD students in the laboratory and several on PhD committees of an additional 2 students

### **INVITED LECTURES AND PRESENTATIONS:**

1. Nerve-sparing radical prostatectomy 2004 Review. Florida Joint Cancer Center Annual Meeting. Orlando, FL Feb. 10-12, 2004.
2. Prostate Cancer in the African-American Community. Prostate cancer: Know the Facts FAMU Symposium on Prostate cancer. Tallahassee, FL Sep. 9, 2004.
3. p37 induces tumor invasiveness. Society for Basic Urologic Research, Savannah, GA Dec. 9-12, 2004.
4. Prostatic intraepithelial neoplasia –what is the significance and how to diagnose. Breast and Prostate Pathology Conference. Amelia Island, FL. Feb. 12-14, 2005.

5. A combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Society for Basic Urologic Research, Miami, FL Dec. 1-4, 2005.
6. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization in the human PC3 prostate tumor model. Society for Basic Urologic Research, Miami, FL Dec. 1-4, 2005.
7. Symptomatic local recurrence of prostate carcinoma after radiation therapy. American Urologic Association, San Antonio, TX May 21-26, 2005.
8. Down regulated of Bcl-2 by Antisense Bcl-2 Oligodeoxynucleotide in the PC-3 Prostate Tumor Model Overexpressing Bcl-2 Induced Synergistic Radiosensitization. American Association Cancer Research, Anaheim, CA Apr. 2005.
9. Impact of Fellowship Training on Pathologic Outcomes and Complication Rates of Radical Prostatectomy. American Association Cancer Research, Anaheim, CA Apr. 2005.
10. Increased expression of COX-2 correlates with resistance to Radiation in human prostate adenocarcinoma cells. American Association Cancer Research, Anaheim, CA Apr. 2005.
11. p37 induces tumor invasiveness. American Association Cancer Research, Anaheim, CA Apr. 2005.
12. Increased expression of COX-2 correlates with resistance to Radiation in human prostate adenocarcinoma cells. Society of Urologic Oncology, Bethesda, MD Dec. 2-5, 2005.
13. p37 induces tumor invasiveness. Society of Urologic Oncology, Bethesda, MD Dec. 2-5, 2005.
14. Prostate Cancer in Duval County. Where do we stand in 2006? Jacksonville, FL Jun. 17, 2006.
15. African American Prostate Cancer: Disparity Summit. House of Congress (Rayburn House Office Building). Washington, DC September 21-22, 2006.
16. Surgical treatment of locally advanced prostate cancer. Controversies in Prostate Cancer Detection. Hawaii, HI Mar. 4-8, 2006.
17. Irradiation increases uptake of antisense oligodeoxynucleotides in human prostate cancer cells. American Urologic Association, Atlanta, GA May 20-25, 2006.
18. Treatment of biochemically recurrent prostate cancer with isoflavones. American Urologic Association, Atlanta, GA May 20-25, 2006.
19. Prostate cancer screening and detection in inner-city and underserved men. American Urologic Association, Atlanta, GA May 20-25, 2006.
20. Interaction of isoflavones and vitamin E with irradiation in androgen independent PC-3 human prostate cancer cells. American Association Cancer Research, Washington DC Apr. 1-5, 2006.
21. Irradiation increases uptake of antisense oligodeoxynucleotides in human prostate cancer cells. American Association Cancer Research, Washington DC Apr. 1-5, 2006.
22. A combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. American Association Cancer Research, Washington DC Apr. 1-5, 2006.
23. Prostate cancer. What a primary care physician should know in 2007. Orlando, FL. Jun. 13, 2007.
24. Genomic Analysis of Shed Urothelia to Detect Bladder Cancer. Florida Cancer Conference, Palm Beach, FL. Sep. 13-15, 2007.

25. Genomic Analysis of Shed Urothelia to Detect Bladder Cancer. Society of Urologic Oncology, Bethesda, MD. November 31-Dec. 1, 2007.
26. Outcomes of Men who Present with Elevated Serum PSA (Greater than 20 ng/mL) to an Inner-City Hospital. American Association Cancer Research, Atlanta, GA. Nov. 27-30, 2007.
27. Knowledge and attitudes of primary care physicians regarding prostate cancer screening American Association Cancer Research, Atlanta, GA. Nov. 27-30, 2007.
28. Prostate cancer knowledge and screening attitudes of inner-city men. American Association Cancer Research, Atlanta, GA. Nov. 27-30, 2007.
29. VEGF treatment of microvascular endothelial cells induces Bcl-2 expression and multiple signaling factors. American Association Cancer Research, San Francisco, CA. Nov. 27-30, 2007.
30. Bcl-2 modulates angiogenesis and lymphangiogenesis in PC-3 xenografts. American Association Cancer Research, San Francisco, CA. Nov. 27-30, 2007.
31. Gene Expression Changes Associated with Growth and Morphologic Effects of Exogenous p37 on Prostate Cancer Cells. American Urologic Association, Anaheim, CA May 25-31, 2007.
32. The Utility Serial Urinalyses and Urinary Cytology in the Evaluation of the Patient with Microscopic Hematuria. American Urologic Association, Anaheim, CA May 25-31, 2007.
33. Exogenous Mycoplasmal p37 Protein Alters Gene Expression, Growth, and Morphology of Prostate Cancer Cells. American Association Cancer Research, Los Angeles, CA. Apr. 14-18, 2007.
34. Prostate and Bladder Cancer Panel – Florida Urological Society, Orlando, FL Sep. 3-4, 2008.
35. High-risk prostate cancer. University of Florida, Gainesville, FL Jan.10, 2008.
36. High-risk prostate cancer. M.D. Anderson Cancer Center, Orlando, FL Feb. 14, 2008.
37. Discovery of bladder cancer biomarkers. M.D. Anderson Orlando Cancer Center- Visiting Professor Feb. 18, 2008.
38. Discovery of bladder cancer biomarkers. Tulane University-Visiting Professor Mar. 21, 2008.
39. Discovery of bladder cancer biomarkers. Wayne State University-Visiting Professor Apr. 14, 2008.
40. Differential effects of soy isoflavones on the tumor microenvironment in human prostate cancer xenografts. American Urological Association Meeting, May 17-22, 2008 Orlando, FL.
41. A combination of soy isoflavone diet and radiation synergistically inhibits the growth of human prostate cancer xenografts. American Association for Cancer Research (AACR) Meeting, Apr. 12-16, 2008, San Diego, CA.
42. VEGF treatment of microvascular endothelial cells induces Bcl-2 expression and multiple signaling factors. American Urological Association, Orlando, FL. May 17-22, 2008.
43. Bcl-2 modulates angiogenesis and lymphangiogenesis in PC-3 xenografts. American Urological Association, Orlando, FL. May 17-22, 2008.
44. Bcl-2 modulates angiogenesis and lymphangiogenesis in PC-3 xenografts. American Association Cancer Research, San Diego, CA. Apr. 12-16, 2008.
45. Genomic Analysis of Shed Urothelia to Detect Bladder Cancer. American Association Cancer Research, San Diego, CA. Apr. 12-16, 2008.



46. Mycoplasmal infection induces malignant transformation of benign prostatic cells. American Association Cancer Research, San Diego, CA. Apr. 12-16, 2008.
47. Genomic Analysis of Shed Urothelia to Detect Bladder Cancer. Southeastern Section of American Urological Association. Mar. 12-14, 2008.
48. Non-muscle invasive bladder cancer. Evaluation and Management – University of Florida, St. Petersburg, FL Feb. 10-12, 2009.
49. The use of genomics to discover urinary biomarkers. Society of Basic Urological Research New Orleans Nov. 5-7, 2009.
50. Biomarkers: Diagnosis and Prognosis. American Association Cancer Research. Denver Colorado Apr. 19-22, 2009.
51. Bladder cancer Biomarkers. 2<sup>nd</sup> Oncology Biomarkers Conference. Miami, FL Jan. 21-23, 2009.
52. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. American Urological Association, Chicago, IL. Apr. 25-29, 2009.
53. Mycoplasmal infection induces malignant transformation of benign prostatic cells. American Urological Association, Chicago, IL. Apr. 25-29, 2009.
54. Bcl-2 modulates angiogenesis and lymphangiogenesis in PC-3 xenografts. American Urological Association, Chicago, IL Apr. 25-29, 2009.
55. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. American Association Cancer Research, Denver, CO Apr. 18-21, 2009.
56. IL-15 in bladder cancer. Section of Immunology and Immunotherapy National Cancer Institute. September 27, 2010.
57. Cryoablation of the Prostate: 2010. George Washington University, Washington, DC. September 29, 2010.
58. Techniques in focal cryosurgical ablation of the prostate. National Medical Association. Orlando, FL Aug. 4, 2010.
59. Focal cryosurgical ablation of the prostate. Southeastern Section of the American Urological Association. Miami, FL Feb. 11-14, 2010.
60. Tissue Ablative Course for Kidney and Prostate. Miami, FL. Nov. 12-13, 2010.
61. PSA Screening in Black Men. Global Prostate Cancer Conference. Jacksonville, FL. Aug. 28, 2010.
62. Locally advanced prostate cancer. Florida Urologic Society, September 3, 2011.
63. Prostate cryoablation: 2011 Update. Bay Area Stone Society. St. Petersburg, FL. Jun 12, 2011.
64. Treatment Options for Non-Muscle Invasive Bladder Cancer. Orlando Nurses Association. Orlando, FL. May 19, 2011.
65. Brazilian Society of Urology. Florianopolis, Brazil November 26, 2011.
66. Tissue Ablative Course for Kidney and Prostate. Anaheim. Oct. 29-30, 2011.
67. Validation of Genomic Profile to Detect Bladder Cancer. American Association Cancer Research, Orlando, FL. Apr. 2-6, 2011.
68. Proteomic Analysis of Voided Urine to Detect Bladder Cancer. American Association Cancer Research, Orlando, FL. Apr. 2-6, 2011.
69. Chronic Mycoplasmal Infection Induces Malignant Transformation of Benign Human Prostate Cells. American Urological Association, Orlando, FL. Apr. 2-6, 2011.

70. Cryoablation of the Prostate: Primary, Salvage and Focal. University of Florida Department of Urology 2012 CME Series Annual Meeting, Orlando, FL. February 17-19, 2012.
71. Molecular biomarker signature for the non-invasive detection of bladder cancer. Society of Basic Urologic Research, Miami, FL November 15-18, 2012.
72. Urinary BTA: Indicator of bladder cancer or of hematuria. Society for Basic Urologic Research. 2012 SBUR Fall Symposium. Miami Beach, FL Nov15 - 18, 2012.
73. Influencing factors on the NMP-22 urinalysis assay: an experimental model. Society for Basic Urologic Research. 2012 SBUR Fall Symposium. Miami Beach, FL Nov15 - 18, 2012.
74. Angiogenesis enhances proliferation and angiogenesis in bladder cancer. Society for Basic Urologic Research. 2012 SBUR Fall Symposium. Miami Beach, FL Nov15 - 18, 2012.
75. Chemokine ligand 1 induces endothelial proliferation and angiogenesis through activating the ERK1/2 EGF pathway mediate by CXC chemokine receptor 2. Society for Basic Urologic Research. 2012 SBUR Fall Symposium. Miami Beach, FL Nov15 - 18, 2012.
76. Molecular biomarker signature for the non-invasive detection of bladder cancer. Society of Basic Urologic Research, Miami, FL November 15-18, 2012.
77. Metabolomic presentation of bladder cancer in urine. American Association Cancer Research Chicago, IL May-April 4, 2012.
78. Molecular biomarker signature for the non-invasive detection of bladder cancer. Southeastern Section of the AUA. Amelia Island, FL. March 22 – 25, 2012.
79. Combinational biomarker assay in the detection of bladder cancer. Southeastern Section of the AUA. Amelia Island, FL March 22 – 25, 2012.
80. IL-15 analogue (ALT-803) causes tumor burden reduction in an orthotopic non-muscle invasive bladder cancer model. AUA Annual Meeting 2013 San Diego, May 4 - 8, 2013
81. Plasminogen activator inhibitor type-1 (PAI-1) enhances bladder cancer tumor progression. AACR Annual Meeting 2013 Washington D.C. Apr 6 - 10, 2013
82. IL-15 analogue (ALT-803) causes tumor burden reduction in an orthotopic non-muscle invasive bladder cancer model. 2013 Genitourinary Cancers Symposium. Orlando, FL Feb 14 - 16, 2013.
83. Validation of a novel diagnostic signature for the detection of bladder cancer in voided urine samples. AUA Annual Meeting 2013 San Diego, May 4 - 8, 2013
84. Angiogenin enhances proliferation and angiogenesis in bladder cancer. AACR Annual Meeting 2013 Washington D.C. Apr 6 - 10, 2013
85. A multi-analyte assay for the noninvasive detection of bladder cancer. 2013 Genitourinary Cancers Symposium. Orlando, FL Feb 14 - 16, 2013.
86. Chemokine ligand 1 induces endothelial proliferation and angiogenesis through activating the ERK1/2/EGF pathway mediate by CXCR2. 2013 Genitourinary Cancers Symposium. Orlando, FL Feb 14 - 16, 2013.
87. Translational Research at UH Hawaii Society Clinical Oncology. Kahala November 14, 2015.
88. Cryoablation of the Prostate: Primary, Salvage and Focal. University of Hawaii Cancer Center February 12, 2015.
89. State of bladder cancer therapy 2015. Western Hawaii Cancer Symposium. Kona Sept 11 and 12 2015.

90. Angiogenin contributes to bladder cancer tumorigenesis by facilitating p53/DNMT3b-mediated activation of MMP2. *Chromatin and Epigenetics in Cancer*. 2015 Atlanta, Sept 24-27, 2015.
91. Phase Ib trial of ALT-803, an IL-15 superagonist, plus Bacillus Calmette Guerin (BCG) for the treatment of patients with BCG-naïve non-muscle-invasive bladder cancer (NMIBC). 2016 Genitourinary Cancers Symposium. San Francisco, January 7-9, 2016.
92. A multiplex immunoassay for the non-invasive detection of bladder cancer. 2016 Genitourinary Cancers Symposium. San Francisco, January 7-9, 2016.
93. Bladder cancer tumor markers. Brigham and Women Hospital. Boston, MA May 12, 2017.
94. Bladder cancer tumor markers. University of Arizona Cancer Center. Tucson, AZ, July 15, 2017.
95. Update on urine-based bladder cancer biomarkers. Fred Hutchinson Cancer Research Center. October 22, 2017.
96. Immunotherapy studies at UHCC. HSCO. Honolulu, HI Nov 11, 2017.
97. Bladder cancer biomarkers: where are we now? JUA, Kyoto, Japan April 22, 2018.
98. Leveraging diagnostic biomarkers to understand tumor biology. UCSF. San Francisco, CA. March 13, 2019.

## **BIBLIOGRAPHY/PUBLICATIONS:**

### **Research Papers – Peer Reviewed**

1. Potter L, **Rosser CJ**, Kroovand L. Prune Belly and VATER association in a newborn infant. Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157. *Digital Urology Journal*.
2. **Rosser CJ**, Bare RL, Hart L, Meredith JW. Urinary tract infections in the critically ill patient with a urinary catheter. *American Journal of Surgery*. 177(4): 287-90, April 1999.
3. **Rosser CJ**, Scharling E, Assimos DG. Leiomyoma of the Scrotum. Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157. *Digital Urology Journal*.
4. **Rosser CJ**, Broberg J, Eskew LA, Case D, McCullough D. Detection of high-grade Prostatic Intraepithelial Neoplasia with the five-region biopsy technique. *Urology*. 54(5): 853-6, Nov. 1999.
5. **Rosser CJ**, Gerrard E. Metastatic Adenocarcinoma of the Pancreas to the Testicle. *American Journal of Clinical Oncology*. 22(6): 619-620, Dec 1999.
6. **Rosser CJ**, Gerrard E. Metastatic Small Cell Carcinoma to the Testicle. *Southern Medical Journal*. 93(1):72-3, Jan 2000.
7. **Rosser CJ**, Morykways M, Bare R, Argenta L. A New Treatment to Manage Perineal Wounds. *Infections in Urology*. 13(2): 45-47, 2000.
8. **Rosser CJ**, Zagoria R, Dixon R, Scurry WC, Bare RL, McCullough D, Assimos D. Is there a learning curve phenomenon in diagnosing a ureteral calculus with non-contrast helical computed tomography? *Canadian Association of Radiology Journal*. 51(3):177-81, June 2000.
9. **Rosser CJ**, McCullough D, Hall MC. Thoracoabdominal radical nephrectomy: is a postoperative thoracostomy tube necessary? *Urology*. 55: 847-851, 2000.
10. Martin JH, **Rosser CJ**, Leinbach F, Patel S, Assimos DG, McCullough DL. Are

- coagulation studies necessary before percutaneous nephrostomy? *Tech in Urol.* 6(3):205-7, Sept 2000.
11. **Rosser CJ**, Hart L, McCullough D. Urodynamic prognostic risk factors in patients with Parkinson Disease undergoing TURP. *Infections in Urology.* 14(1):23-28, May/June 2001.
  12. Zhou J, **Rosser CJ**, Tanaka M, Yang M, Baranov E, Hoffman RM, Benedict WF. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. *Cancer Gene Ther.* 9(8):681-6, Aug. 2002.
  13. Yamashita M, **Rosser CJ**, Zhou J, Zhang X, Conner RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CPN, Benedict WF. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. *Cancer Gene Ther.* 9(8):687-91, Aug. 2002.
  14. **Rosser CJ**, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, Pisters LL. The PSA “Bounce” Phenomenon after External Beam Radiation for Clinically Localized Prostate Cancer. *J. Urol.* 168(5), Nov. 2002.
  15. **Rosser CJ**, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical Disease-Free Survival in Men Younger than 60 Years with Prostate Cancer Treated by External-Beam Radiation. *J. Urol.* 168(2):536-41, Aug. 2002.
  16. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, **Rosser CJ**, Pathak S, Benedict WF. Adenoviral-mediated Rentinoblastoma 94 Produces Rapid Telomere Erosion, Chromosomal Crisis, and Caspase-dependent Apoptosis in Bladder Cancer and Immortalized Human Urothelial Cells but not in Normal Urothelial Cells. *Cancer Res.* 63, 760-765, Feb 2003.
  17. Rao A, Chang BL, Hawkins GA, Hu JJ, **Rosser CJ**, Hall MC, Meyers DA, Xu JF, Cramer SD. Analysis of the G/A Polymorphism in the Androgen Response Element I of the PSA Gene and Its Interactions with Androgen Receptor Polymorphisms. *Urology:* 61:864-869, 2003.
  18. **Rosser CJ**, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma compared to localized radio-naive prostate carcinoma. *Int J Radiat Oncol Biol Phys.* 56(1): 1-6, 2003.
  19. **Rosser CJ**, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical Features and Treatment Outcome of Hispanic Men with Prostate Cancer following External-Beam Radiotherapy. *J Urol.* 170(5): 1856-9, 2003.
  20. **Rosser CJ**, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL. Hazard Rates of Disease Progression after External-Beam Radiotherapy for Clinically Localized Carcinoma of the Prostate. *J Urol.* 169(6): 2160-5, 2003.
  21. **Rosser CJ**, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. *Urology.* 61:1151, 2003.
  22. Tanaka M, Gee JR, DeLaCerde J, **Rosser CJ**, Zhou JH, Benedict WF, Grossman HB. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. *J Urol.* 170(3):975-8, 2003.
  23. **Rosser CJ**, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. *J Urol.* 170:1856, 2003.
  24. Kamat AM, Huang SF, Bermejo CE, **Rosser CJ**, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with

- locally recurrent prostate cancer. *J Urol.* 170(5):1868-71, 2003.
25. **Rosser CJ**, Kroovand RL. VURD syndrome managed by pyelostomy. *Scientific World Journal.* 4:382-6, 2004.
  26. Kamat AM, Shock RP, Nara Y, **Rosser CJ**, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. *Urology.* 63:46, 2004.
  27. **Rosser CJ**, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RA. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2 expressing prostate cancer cells to radiation. *Cancer Gene Therapy.* Feb 2004.
  28. Sanchez-Ortiz R, **Rosser CJ**, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. *J Urol.* 2004 Jun;171(6 Pt 1):2160-5.
  29. Kamat AM, **Rosser CJ**, Levy LB, Chichakli R, Lee AK, Cheung RM, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. *Urology.* 2004 Jun;63(6):1132-7.
  30. **Rosser CJ**, Kuban DA, Lee SJ, Levy LB, Pettaway CA, Kamat AM, Chichakli R, Lee AK, Cheung RM, Sanchez-Ortiz, R, Pisters, LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. *J Natl Med Assoc.* 2004 Jul;96(7):939-44.
  31. **Rosser CJ**, Tanaka N, Stafford RJ, Price RE, Hazle JD, Tanaka M, Kamat AM, Pisters LL. Feasibility to delineate distribution of solution injected intraprostatic using an ex-vivo canine model. *Gene Ther Mol Biol.* 8:509-514, 2004.
  32. Leibovici D, Pagliaro L, **Rosser CJ**, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. *J Urol.* 173:781-3, 2005.
  33. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, **Rosser CJ**, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. *Cancer.* 103:2060-6, 2005.
  34. Tanaka M, **Rosser CJ**, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. *Cancer Detect Prev.* 29:170-4, 2005.
  35. Ketcham CM, Anai S, Reutzel R, Sheng S, Schuster SM, Brenes RB, Agbandje-McKenna M, McKenna R, **Rosser CJ**, Boehlein SK. P37 induces tumor invasiveness. *Mol Cancer Ther.* 2005 Jul;4(7):1031-8.
  36. **Rosser CJ**, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? *Urology.* 2005 Aug;66(2):327-31.
  37. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, **Rosser CJ**, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. *J Urol.* 2005 Dec;174(6):2186-90.
  38. **Rosser CJ**, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. *Urology.* 2006 Apr;67(4):769-73. Epub 2006 Apr 11.
  39. Anai S, Pendleton J, Wludyka P, Williams C, Nelms L, Pettaway C, **Rosser CJ**. Prostate

- cancer screening and detection in inner-city and underserved men. *J Natl Med Assoc.* 2006 Apr;98(4):515-9.
40. **Rosser CJ**, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. *Cancer.* 2006 Jul 1;107(1):54-9.
  41. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, **Rosser CJ**, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. *Cancer.* 2006 Aug 1;107(3):631-9.
  42. Pendleton J, Costa J, Wludyka P, Carvin DM, **Rosser CJ**. Combination of oral tramadol, acetaminophen and 1% lidocaine induced periprostatic nerve block for pain control during transrectal ultrasound guided biopsy of the prostate: a prospective, randomized, controlled trial. *J Urol.* 2006 Oct;176(4 Pt 1):1372-5.
  43. Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, **Rosser CJ**. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. *Hum Gene Ther.* 2006 Oct;17(10):975-84.
  44. Rice L, Handayani R, Cui Y, Medrano T, Samedi V, Baker H, Szabo NJ, **Rosser CJ**, Goodison S, Shiverick KT. Soy Isoflavones Exert Differential Effects on Androgen Responsive Genes in LNCaP Human Prostate Cancer Cells. *J Nutr.* 2007 Apr;137(4):964-972.
  45. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, **Rosser CJ**. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts *Mol Cancer Ther* 2007 6: 101-111.
  46. Anai S, Brown BD, Nakamura K, Goodison S, Hirao Y, **Rosser CJ**. Irradiation of Human Prostate Cancer Cells Increases Uptake of Antisense Oligodeoxynucleotide. *Int J Radiat Oncol Biol Phys.* 2007 Jul 15;68(4):1161-8.
  47. Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, Goodison S, Mizokami A, **Rosser CJ**. Increased expression of COX-2 correlates with resistance to Radiation in human prostate adenocarcinoma cells. *J Urol.* 2007 May;177(5):1913-7.
  48. Nakamura K, Kasraeian A, Yacoub SM, Pendleton JM, Anai S, **Rosser CJ**. The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. *Int Braz J Urol.* 2007 May-Jun;33(3):347-52; discussion 352-4.
  49. Nakamura K, Kasraeian A, Anai S, Pendleton J, **Rosser CJ**. Positive surgical margins at radical prostatectomy: importance of intra-operative bladder neck frozen sections. *Int Braz J Urol.* 2007 Nov-Dec;33(6):746-51.
  50. Kreunin P, Zhao J, **Rosser C**, Urquidi V, Lubman DM, Goodison S. Bladder Cancer Associated Glycoprotein Signatures revealed by Urinary Proteomic Profiling. *J Proteome Res.* 2007 Jul;6(7):2631-9.
  51. Goodison S, Nakamura K, Iczkowski KA, Anai S, Boehlein SK, **Rosser CJ**. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. *Cytogenet Genome Res.* 2007;118(2-4):204-13.
  52. Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD, **Rosser CJ**. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. *Urology.* 2007 Oct;70(4):832-7.

53. Anai S, West CS, Chang M, Nakamura K, Pendleton J, **Rosser CJ**. Outcomes of men who present with elevated serum PSA (>20 ng/mL) to an inner-city hospital. *J Natl Med Assoc.* 2007 Aug;99(8):895-9.
54. Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, **Rosser CJ**, Stephens C, Tinkey PT, Pisters LL. An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. *Urology.* 2007 Oct;70(4):822-5.
55. Anai S, Nakamura K, Pendleton J, Gaar M, Yacoub S, **Rosser CJ**. The feasibility of watchful waiting in inner-city men with newly diagnosed localized prostate cancer. *J Health Care Poor Underserved.* 2008 Feb;19(1):164-70.
56. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, **Rosser CJ**. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. *Prostate.* 2008 Aug 1;68(11):1223-31.
57. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, **Rosser CJ**. Phase II Trial of Isoflavone in prostate specific antigen recurrent prostate cancer after previous local therapy. *BMC Cancer.* 2008 May 11;8(1):132.
58. Cao W, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, **Rosser CJ**. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. *World J Urol.* 2008 Jul 2.
59. Pendleton J, Hopkins C, Anai S, Nakamura K, Chang M, Grissett A, **Rosser CJ**. Prostate cancer knowledge and screening attitudes of inner-city men. *J Cancer Educ.* 2008;23(3):172-9.
60. Pendleton J, Curry RW, Kaserian A, Chang M, Anai S, Nakamura K, Abdoush P, **Rosser CJ**. Knowledge and attitudes of primary care physicians regarding prostate cancer screening. *J Natl Med Assoc.* 2008 Jun;100(6):666-70.
61. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, **Rosser CJ**, Uemura H, Hirao Y. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. *Mol Cancer Ther.* 2008 Jul;7(7):1864-70.
62. Kusmartsev S, Eruslanov E, Kübler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, **Rosser C**, Dahm P, Siemann D, Vieweg J. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. *J Immunol.* 2008 Jul 1;181(1):346-53.
63. Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, **Rosser CJ**. Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. *Prostate.* 2008 Dec 23.
64. Sippel KH, Robbins AH, Reutzel R, Domsic J, Boehlein SK, Govindasamy L, Agbandje-McKenna M, **Rosser CJ**, McKenna R. Structure determination of the cancer-associated *Mycoplasma hyorhina* protein Mh-p37. *Acta Crystallographica.* 2008 64(11): 1172-1178.
65. Genis C, Sippel KH, Case N, Cao W, Avvaru BS, Tartaglia LJ, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, **Rosser CJ**, McKenna R. Design of a Carbonic Anhydrase IX Active-Site Mimic To Screen Inhibitors for Possible Anticancer Properties (dagger) (double dagger). *Biochemistry.* 2009 Jan 26.
66. Sippel KH, Robbins AH, Reutzel R, Boehlein SK, Namiki K, Goodison S, Agbandje-McKenna M, **Rosser CJ**, McKenna R. Structural insights into the extracytoplasmic thiamine-binding lipoprotein p37 of *Mycoplasma hyorhina*. *J Bacteriol.* 2009 Apr;191(8):2585-92.

67. Namiki K, Kasraeian A, Yacoub S, **Rosser CJ**. Blunt apical dissection during anatomic radical retropubic prostatectomy. *BMC Res Notes*. 2009 Feb 6;2:20.
68. **Rosser CJ**, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder Cancer-Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia. *Cancer Epidemiol Biomarkers Prev*. 2009 Feb 3.
69. Sakai Y, Goodison S, Cao W, Urquidi V, Namiki K, Porvasnik S, Urbanek C, **Rosser CJ**. VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells in a prostate cancer model. *World J Urol*. 2009 Jun 4.
70. Urbanek C, Turpen R, **Rosser CJ**. Radical Prostatectomy: Hospital volumes and surgical volumes - does practice make perfect? *BMC Surg*. 2009 Jun 6;9(1):10.
71. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, **Rosser CJ**. Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer. *Urol Oncol*. 2009 Jul 2.
72. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, **Rosser CJ**. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. *Prostate*. 2009 Sep 15;69(13):1460-9.
73. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, **Rosser CJ**. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. *PLoS One*. 2009 Sep 1;4(9):e6872.
74. Sippel KH, Boehlein SK, Sakai Y, Quirit JG, Agbandje-McKenna M, **Rosser CJ**, McKenna R. Cloning, expression, purification, crystallization and preliminary X-ray analysis of Mycoplasma genitalium protein MG289. *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2009 Sep 1;65(Pt 9):910-2.
75. Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, **Rosser CJ**. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. *BMC Urol*. 2009 Sep 10;9:12.
76. Nakamura K, Yamada Y, **Rosser CJ**, Aoki S, Taki T, Honda N. Holmium YAG laser ablation of a hemangioma involving a lower pole renal calyx - using the new-generation flexible ureteroscope URF type P5: a case report. *Cases J*. 2009 Jun 17;2:7780.
77. Arakawa M, Nakamura K, Yamada Y, **Rosser CJ**, Tobiume M, Saito H, Hasegawa T, Honda N. Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report. *BMC Urol*. 2010 Feb 26;10:6.
78. Bovio IM, Al-Quran SZ, **Rosser CJ**, Algood CB, Drew PA, Allan RW. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. *Histopathology*. 2010 Jun;56(7):951-6.
79. Nakamura K, Iczkowski KA, Chang M, Pendleton J, Anai S, Le NP, **Rosser CJ**. The Utility Serial Urinary Cytology. *BMC Urol* 2009 Sept 10;9:12.
80. Sippel KH, Venkatakrisnan B, Boehlein SK, Sankaran B, Quirit JG, Govindasamy L, Agbandje-McKenna M, Goodison S, **Rosser CJ**, McKenna R. Insights into Mycoplasma genitalium metabolism revealed by the structure of MG289, an extracytoplasmic thiamine binding lipoprotein. *Proteins*. 2011 Feb;79(2):528-36.
81. Yang N, Feng S, Shedden K, Xie X, Liu Y, **Rosser CJ**, Lubman DM, Goodison S. Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification. *Clin Cancer Res*. 2011 May 15;17(10):3349-59.
82. **Rosser CJ**, Nakamura K, Pendleton J, Anal S, Chang M, Kasraelan A, Yeung L. Utility of serial urinalyses in the evaluation of patients with microscopic haematuria. *West Afr J*



- Med. 2010 Nov-Dec;29(6):384-7.
83. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, **Rosser C**, Vieweg J, Gilbert SM, Kusmartsev S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. *Int J Cancer*. 2011 Apr 7.
  84. Li CZ, Vandenberg K, Prabhulkar S, Zhu X, Schneper L, Methee K, **Rosser CJ**, Almeida E. Paper based point-of-care testing disc for multiplex whole cell bacteria analysis. *Biosens Bioelectron*. 2011 Apr 28.
  85. Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, **Rosser CJ**, Su LM, Vieweg J, Kusmartsev S. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. *Cancer Res*. 2011 Oct 15;71(20):6400-9. Epub 2011 Sep 7.
  86. Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, **Rosser CJ**. Detection of antibodies directed at M. hyorhinitis p37 in the serum of men with newly diagnosed prostate cancer. *BMC Cancer*. 2011 Jun 10;11(1):233.
  87. Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, **Rosser CJ**, Wood CG, Matin SF. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. *J. Urol*. 2012 Mar;187(3):822-6.
  88. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, **Rosser CJ**. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. *Urology*. 2012 May;79(5):1185.e1-6. Epub 2012 Mar 3.
  89. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, **Rosser CJ**. IL-8 as a urinary biomarker for the detection of bladder cancer. *BMC Urol*. 2012 May 4;12(1):12.
  90. Urquidi V, Kim J, Chang M, Dai Y, **Rosser CJ**, Goodison S. CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer. *PLoS One*. 2012;7(5):e37797. Epub 2012 May 21.
  91. Miyake M, Goodison S, Gomes Giacoia E, Rizwani W, Ross S, **Rosser CJ**. Influencing factors on the NMP-22 urinalysis assay: an experimental model. *BMC Urol*. 2012 Aug 28;12(1):23.
  92. Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, **Rosser CJ**. Urinary BTA: indicator of bladder cancer or of hematuria. *World J Urol*. 2012 Aug 30.
  93. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, **Rosser CJ**. Diagnostic Potential of Urinary  $\alpha$ 1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. *J Urol*. 2012 Oct 19.
  94. Goodison S, Chang M, Dai Y, Urquidi V, **Rosser CJ**. A multi-analyte assay for the non-invasive detection of bladder cancer. *PLoS One*. 2012;7(10).
  95. Urquidi V, Goodison S, Cai Y, Sun Y, **Rosser CJ**. A Candidate Molecular Biomarker Panel for the Detection of Bladder Cancer. *Cancer Epidemiol Biomarkers Prev*. 2012 Oct 24.
  96. Hale Z, Miyake M, Palacios DA, **Rosser CJ**. Focal cryosurgical ablation of the prostate: a single institute's perspective. *BMC Urol*. 2013 Jan 11;13(1):2. [Epub ahead of print]
  97. Urquidi V, Goodison S, **Rosser CJ**. Diagnostic Potential of Urinary  $\alpha$ 1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. *J Urol*. 2013 Jan 12. doi:pii: S0022-5347(13)00051-7.
  98. Goodison S, Urquidi V, Kumar D, Reyes L, **Rosser CJ**. Complete Genome Sequence of Mycoplasma hyorhinitis Strain SK76. *Genome Announc*. 2013 Jan;1(1). doi:pii: e00101-12. 10.1128/genomeA.00101-12. Epub 2013 Feb 7.

99. Beilan J, Lawton A, Hajdenberg J, **Rosser CJ**. Locally advanced paraganglioma of the urinary bladder: a case report. *BMC Res Notes*. 2013 Apr 18;6:156.
100. Hale Z, Hanna E, Miyake M, **Rosser CJ**. Imaging the urologic patient: the utility of intravenous pyelogram in the CT scan era. *World J Urol*. 2013 Apr 25. [Epub ahead of print]
101. Beilan J, Lawton A, Hajdenberg J, **Rosser CJ**. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. *BMC Urol*. 2013 Apr 29;13(1):22.
102. Chen LM, Nergard JC, Ni L, **Rosser CJ**, Chai KX. Long-Term Exposure to Cigarette Smoke Extract Induces Hypomethylation at the RUNX3 and IGF2-H19 Loci in Immortalized Human Urothelial Cells. *PLoS One*. 2013 May 28;8(5):e65513. doi: 10.1371/journal.pone.0065513.
103. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, **Rosser CJ**. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. *Lab Invest*. 2013 Jul;93(7):768-78.
104. **Rosser CJ**, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S. Multiplex Protein Signature for the Detection of Bladder Cancer in Voided Urine Samples. *J Urol*. 2013 Jun 10. doi:pii: S0022-5347(13)04581-3.
105. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, **Rosser CJ**. Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. *BMC Cancer*. 2013 Jul 1;13:322. doi: 10.1186/1471-2407-13-322.
106. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, **Rosser CJ**. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. *J Hematol Oncol*. 2013 Sep 3;6(1):65.
107. Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S, **Rosser CJ**. Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. *BMC Urol*. 2013 Sep 5;13(1):42.
108. Gomes-Giacoia E, Miyake M, Goodison S, **Rosser CJ**. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. *Mol Cancer Ther*. 12:2697-708, 2013.
109. Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, **Rosser CJ**, Soloway MS, Lokeshwar VB. Differential Expression Of Stroma Derived Factor-1 Isoforms In Bladder Cancer. *J Urol*. 2013 Nov 26. pii: S0022-5347(13)06007-2.
110. Gomes Giacoia E, Miyake M, Lawton A, Goodison S, **Rosser CJ**. PAI-1 Leads to G1-phase Cell Cycle Progression through Cyclin D3/CDK4/6 Up-regulation. *Mol Cancer Res*. 2014 Jan 24.
111. Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, **Rosser CJ**. Angiogenin promotes tumoral growth and angiogenesis by regulating MMP2 expression via the ERK1/2 pathway. *Oncogene*. 2014.
112. **Rosser CJ**, Dai Y, Miyake M, Zhang G, Goodison S. Simultaneous multi-analyte urinary protein assay for bladder cancer detection. *BMC Biotechnol*. 2014 Apr 1;14:24. doi: 10.1186/1472-6750-14-24.
113. **Rosser CJ**, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S. Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer. *Cancer Epidemiol*

- Biomarkers Prev. 2014 Apr 8.
114. Zhang G, Miyake M, Lawton A, Goodison S, **Rosser CJ**. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. *BMC Cancer*. 2014 May 3;14(1):310. doi: 10.1186/1471-2407-14-310.
  115. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, **Rosser CJ**. Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion. *PLoS One*. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705.
  116. DeDeugd, C, Miyake, M, Palacios, DA, & **Rosser, CJ**. (2014). The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer. *Journal of Racial and Ethnic Health Disparities*, 1-8.
  117. Chen LM, Chang M, Dai Y, Chai KX, Dyrskjöt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, **Rosser CJ**. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. *Cancer Epidemiol Biomarkers Prev*. 2014 Sep;23(9):1804-12.
  118. Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, **Rosser CJ**. Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. *Diagn Pathol*. 2014 Nov 12;9:200.
  119. Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist M, Goodison S, **Rosser CJ**. A multiplex immunoassay for the non-invasive detection of bladder cancer, *J Transl Med*. 2016 Jan 30;14:31.
  120. Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, **Rosser CJ**, Furuya H. CXCL1 is elevated in the urine of bladder cancer patients. *Springerplus*. 2015 Oct 15;4:610. doi: 10.1186/s40064-015-1393-9. eCollection 2015.
  121. Paladino D, Yue P, Furuya H, Acoba J, **Rosser CJ**, Turkson J. A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. *Oncotarget*. 2016 Feb 9;7(6):7253-67. doi: 10.18632/oncotarget.6635.
  122. Ho ME, Quek SI, True LD, Seiler R, Fleischmann A, Bagryanova L, Kim SR, Chia D, Goodglick L, Shimizu Y, **Rosser CJ**, Gao Y, Liu AY. Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. *Oncotarget*. 2016 Feb 15. doi: 10.18632/oncotarget.7400. [Epub ahead of print]
  123. Peres H, Furuya H, Pagano I, Shimizu Y, Hokutan K, **Rosser CJ**. Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b mediated MMP2 activation. *Oncotarget* 2015 June 1.
  124. Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, **Rosser CJ**, Goodison S. A microRNA biomarker panel for the non-invasive detection of bladder cancer. *Oncotarget*. 2016 Dec 27;7(52):86290-86299. doi: 10.18632/oncotarget.13382.
  125. Urquidi V, Netherton M, Gomes-Giacoia E, Serie D, Eckel-Passow J, **Rosser CJ**, Goodison S. Urinary mRNA biomarker panel for the detection of urothelial carcinoma. *Oncotarget*. 2016 May 25.
  126. Huang S, Kou L, Furuya H, Yu C, Goodison S, Kattan MW, Garmire L, **Rosser, CJ**. A nomogram derived by combination of demographic and biomarker data improves the noninvasive evaluation of patients at risk for bladder cancer. *Cancer Epidemiol Biomarkers Prev*. 2016 Sept;25(9):1361-6.

127. Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, **Rosser CJ**. A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. *J Transl Med*. 2016.
128. Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, **Rosser CJ**, Fujimoto K. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. *Neoplasia*. 2017 Mar;19(3):250-251. doi: 10.1016/j.neo.2016.12.012. No abstract available.
129. Huang J, Schisler J, Wong HC, **Rosser CJ**, Sterbis J. Intravesical ALT-803 for BCG-unresponsive Bladder Cancer - A Case Report. *Urol Case Rep*. 2017 Jun 8;14:15-17. doi: 10.1016/j.eucr.2017.04.015. eCollection 2017 Sep.
130. Shimizu Y, Furuya H, Tamashiro PM, Iino K, Chan OTM, Goodison S, Pagano I, Hokutan K, Peres R, Loo LWM, Hernandez B, Naing A, Chong CDK, **Rosser CJ**, Kawamori T. Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model. *Carcinogenesis*. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.
131. Chan OTM, Furuya H, Pagano I, Shimizu Y, Hokutan K, Dyrskjøt L, Jensen JB, Malmstrom PU, Segersten U, Janku F, **Rosser CJ**. Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. *Oncotarget*. 2017 Sep 6;8(59):99707-99721. doi: 10.18632/oncotarget.20686. eCollection 2017 Nov 21.
132. Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, **Rosser CJ**, Rose JM, Giffin LC, Gonzalez LE, Chamie K. Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer. *Cancer Epidemiol Biomarkers Prev*. 2018 Dec 28. pii: cebp.0893.2018. doi: 10.1158/1055-9965.EPI-18-0893. [Epub ahead of print]
133. Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, **Rosser CJ**. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. *J Transl Med*. 2019 Jan 17;17(1):29. doi: 10.1186/s12967-019-1778-6.
134. Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, **Rosser CJ**. Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. *Theranostics*. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.
135. Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, Furuya H, **Rosser CJ**, Fujimoto K. Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. *Cells*. 2019 Mar 2;8(3). pii: E212. doi: 10.3390/cells8030212.

### Chapters:

1. **Rosser CJ**, Benedict JF, Zagoria R, Jarow JP. Imaging of the Male Reproductive Tract for Infertility. *Atlas of Urologic Clinics of North America* April 1999.
2. Yeung, L, **Rosser, CJ**. Surgical treatment options for locally advanced prostate cancer in Evidence-Based Urology. Editor P. Dahm, 2010.

3. **Rosser, CJ.** Cancer Biology in Essential and Updates in Urologic Oncology. Editor P. Spiess, 2011.

#### **Letters Editor:**

1. **Rosser CJ.** Editorial Comment. *J Urol.* 2009 Sep 15.
2. **Rosser CJ.** Editorial comment. *Urology.* 2010 Jan;75(1):132; author reply 132-3.
3. Furuya H, **Rosser CJ**, Inman BA, Fantony JJ. Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'. *J Natl Compr Canc Netw.* 2017 May;15(5).

#### **Reviews:**

1. **Rosser CJ**, McCullough D. Penile Cancer in *Cancer Consults*, 1998.
2. **Rosser CJ**, Benedict WF, Dinney CPN. Gene Therapy for Superficial Bladder Cancer. *Exp Rev Anticancer Ther.* 1:531-540, 2001.
3. Pendleton J, Pisters LL, Nakamura K, Anai S, **Rosser CJ.** Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going? *Urol Oncol.* 2007 Jan-Feb;25(1):11-8.
4. Namiki K, **Rosser CJ.** Neoadjuvant therapy and prostate cancer: what a urologist should know. *Curr Opin Urol.* 2007 May;17(3):188-93.
5. Dahm P, **Rosser CJ**, McKiernan JM. Quality of care for testis cancer. *UrolOncol.* 2009 Jul-Aug;27(4):448-53. Review.
6. **Rosser CJ**, Gaar M, Porvasnik S. Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? *BMC Cancer.* 2009 Jul 9;9:225.
7. Goodison S, **Rosser CJ**, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. *Expert Rev Proteomics.* 2009 Oct;6(5):507-14.
8. Villicana P, Whiting B, Goodison S, **Rosser CJ.** Urine-based assays for the detection of bladder cancer. *Biomark Med.* 2009 Jun 1;3(3):265.
9. **Rosser CJ**, Goodison S. Research highlights. *Biomark Med.* 2010 Aug;4(4):495-7.
10. Urquidi V, **Rosser CJ**, Goodison S. Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis. *Curr Med Chem.* 2012 Jun 7.
11. Miyake M, Giacoia EG, Palacios DA, **Rosser CJ.** Research Highlights: Highlights from the latest articles in biomarkers in medicine. *Biomark Med.* 2012 Aug;6(4):511-5. No abstract available.
12. Palacios DA, Miyake M, **Rosser CJ.** Radiosensitization in prostate cancer: mechanisms and targets. *BMC Urol.* 2013 Jan 26;13(1):4.
13. Goodison S, **Rosser CJ**, Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. *Mol Diagn Ther.* 2013 Apr;17(2):71-84.
14. Szarvas T, Nyirády P, Ogawa O, Furuya H, **Rosser CJ**, Kobayashi T. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. *Methods Mol Biol.* 2018;1655:251-273. doi: 10.1007/978-1-4939-7234-0\_19. Review. Erratum in: *Methods Mol Biol.* 2018;1655:E1.
15. Faiena I, **Rosser CJ**, Chamie K, Furuya H. Diagnostic biomarkers in non-muscle invasive bladder cancer. *World J Urol.* 2018 Nov 22. doi: 10.1007/s00345-018-2567-1. [Epub ahead of print]

#### **Editorials:**

1. **Rosser CJ**, Parker A.: The prostate specific antigen era in the United States is over for

- prostate cancer: what happened in the last 20 years? *J Urol*. 2005 Sep;174(3):1154-5; author reply 1155-6.
2. **Rosser CJ**. Prostate Cancer - To screen, or not to screen, is that the question? *BMC Urol*. 2008 Dec 23;8(1):20.
  3. Turpen R, **Rosser CJ**. Focal therapy for prostate cancer: revolution or evolution? *BMC Urol*. 2009 Apr 23;9(1):2.
  4. **Rosser CJ**, Goodison S. Today's discoveries to tomorrow's care: cancer biomarkers revisited. Foreword. *Biomark Med*. 2010 Aug;4(4):491-3.
  5. **Rosser CJ**, Goodison S. CD24, a promising biomarker in NSCLC. *Biomark Med*. 2010 Aug;4(4):495.
  6. **Rosser CJ**, Goodison S. From gene to protein expression: improving prognostication of DCIS. *Biomark Med*. 2010 Aug;4(4):496-7.
  7. **Rosser CJ**, Goodison S. Novel approach for oral cancer biomarker discovery. *Biomark Med*. 2010 Aug;4(4):495-6.
  8. Miyake M, Gomes Giacoia E, Aguilar Palacios D, **Rosser CJ**. Lung cancer risk assessment for smokers: gene promoter methylation signature in sputum. *Biomark Med*. 2012 Aug;6(4):512.
  9. Miyake M, Gomes Giacoia E, Aguilar Palacios D, **Rosser CJ**. Sarcosine, a biomarker for prostate cancer: ready for prime time? *Biomark Med*. 2012 Aug;6(4):513-4.
  10. Miyake M, Gomes Giacoia E, Aguilar Palacios D, **Rosser CJ**. Biomarker linking inflammation to the pathogenesis of cardiovascular disease. *Biomark Med*. 2012 Aug;6(4):514-5.
  11. Palacios DA, Miyake M, **Rosser CJ**. Research Highlights: Highlights from the latest articles in biomarkers in medicine. *Biomarkers in Medicine*, December 2013, Vol. 7, No. 6, Pages 923-928.
  12. Furuya H, Brenner D, **Rosser CJ**. On the brink of extinction: the future of translational physician-scientists in the United States. *J Transl Med*. 2017 May 1;15(1):88. doi: 10.1186/s12967-017-1188-6.
  13. **Rosser CJ**. Nutritional implications for quality of life in bladder cancer survivors. *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S688-S691. doi: 10.21037/tau.2018.12.02. No abstract available.